Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis

Staub, 2013, The antiphospholipid syndrome and Tregs, Autoimmun Rev

Mahler, 2012, Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome, Autoimmun Rev, 12, 313, 10.1016/j.autrev.2012.05.006

Ruiz-Irastorza, 2010, Antiphospholipid syndrome, Lancet, 376, 1498, 10.1016/S0140-6736(10)60709-X

Pierangeli, 2011, Standards and reference materials for the anticardiolipin and anti-beta2glycoprotein I assays: a report of recommendations from the APL task force at the 13th International Congress on antiphospholipid antibodies, Clin Chim Acta, 413, 358, 10.1016/j.cca.2011.09.048

Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost, 4, 295, 10.1111/j.1538-7836.2006.01753.x

Tozzoli, 2014, Autoantibody profiling of patients with antiphospholipid syndrome using an automated multiplexed immunoassay system, Autoimmun Rev, 13, 59, 10.1016/j.autrev.2013.08.007

Pengo, 2013, Correct laboratory approach to APS diagnosis and monitoring, Autoimmun Rev, 12, 832, 10.1016/j.autrev.2012.11.008

Roggenbuck, 2012, Antiphospholipid antibody profiling: time for a new technical approach?, Autoimmun Rev, 11, 821, 10.1016/j.autrev.2012.02.016

Ruiz-Irastorza, 2011, Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies, Lupus, 20, 206, 10.1177/0961203310395803

Staub, 2012, Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome, Autoimmun Rev, 12, 230, 10.1016/j.autrev.2012.07.008

Galarza-Maldonado, 2012, Obstetric antiphospholipid syndrome, Autoimmun Rev, 11, 288, 10.1016/j.autrev.2011.10.006

Pengo, 2012, High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: ‘PROS’ and ‘CONS’, Autoimmun Rev, 11, 577, 10.1016/j.autrev.2011.10.016

Ceccarelli, 2012, Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: “pros” and “cons”, Autoimmun Rev, 11, 568, 10.1016/j.autrev.2011.10.014

Berger, 2009, Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials, JAMA, 301, 1909, 10.1001/jama.2009.623

Becattini, 2012, Aspirin for preventing the recurrence of venous thromboembolism, N Engl J Med, 366, 1959, 10.1056/NEJMoa1114238

Stroup, 2000, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group, JAMA, 283, 2008, 10.1001/jama.283.15.2008

Forastiero, 2005, A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis, J Thromb Haemost, 3, 1231, 10.1111/j.1538-7836.2005.01295.x

Hereng, 2008, Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients, Lupus, 17, 11, 10.1177/0961203307084724

Cervera, 2009, Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients, Ann Rheum Dis, 68, 1428, 10.1136/ard.2008.093179

Giron-Gonzalez, 2004, Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals, J Rheumatol, 31, 1560

Brandt, 1995, Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH, Thromb Haemost, 74, 1185, 10.1055/s-0038-1649901

Pengo, 2009, Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, J Thromb Haemost, 7, 1737, 10.1111/j.1538-7836.2009.03555.x

Wilson, 1999, International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop, Arthritis Rheum, 42, 1309, 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F

Hochberg, 1997, Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum, 40, 1725, 10.1002/art.1780400928

Ruffatti, 2011, Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study, Ann Rheum Dis, 70, 1083, 10.1136/ard.2010.142042

Ruffatti, 2009, Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study, Ann Rheum Dis, 68, 397, 10.1136/ard.2008.096669

Tarr, 2007, Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients, Lupus, 16, 39, 10.1177/0961203306074767

Tarr, 2007, Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up, Clin Rev Allergy Immunol, 32, 131, 10.1007/s12016-007-0009-8

Pengo, 2011, Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study, Blood, 118, 4714, 10.1182/blood-2011-03-340232

Wahl, 1997, Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—a meta-analysis, Lupus, 6, 467, 10.1177/096120339700600510

Wahl, 1998, Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis, Lupus, 7, 15, 10.1191/096120398678919688

Zuily, 2012, Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies, Circulation, 124, 215, 10.1161/CIRCULATIONAHA.111.028522

Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629

Erkan, 2007, Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals, Arthritis Rheum, 56, 2382, 10.1002/art.22663

Erkan, 2001, High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin, Arthritis Rheum, 44, 1466, 10.1002/1529-0131(200106)44:6<1466::AID-ART242>3.0.CO;2-C

Martinez-Zamora, 2012, Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease, Clin Rev Allergy Immunol, 43, 265, 10.1007/s12016-012-8316-0

Tektonidou, 2009, Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies, Arthritis Rheum, 61, 29, 10.1002/art.24232

Erkan, 2002, A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome, Rheumatology (Oxford), 41, 924, 10.1093/rheumatology/41.8.924

Ginsburg, 1992, Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis, Ann Intern Med, 117, 997, 10.7326/0003-4819-117-12-997

Kaiser, 2009, Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort, Ann Rheum Dis, 68, 238, 10.1136/ard.2008.093013

Mok, 2005, Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus, J Rheumatol, 32, 622

Shah, 1998, Outcome of patients with anticardiolipin antibodies: a 10year follow-up of 52 patients, Lupus, 7, 3, 10.1191/096120398678919624

Tincani, 2002, Thromboembolic events after fetal loss in patients with antiphospholipid syndrome: comment on the article by Erkan et al, Arthritis Rheum, 46, 1126, 10.1002/art.10165

Wahl, 2000, Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis, Arch Intern Med, 160, 2042, 10.1001/archinte.160.13.2042

Reiner, 2011, Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies, Mov Disord, 26, 2422, 10.1002/mds.23863

Rodrigues, 2012, Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome, Arthritis Care Res (Hoboken), 64, 1576, 10.1002/acr.21701

Urbanus, 2009, Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case–control study, Lancet Neurol, 8, 998, 10.1016/S1474-4422(09)70239-X

Ruiz-Irastorza, 2008, Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review, Ann Rheum Dis, 69, 20, 10.1136/ard.2008.101766

Seshasai, 2012, Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials, Arch Intern Med, 172, 209, 10.1001/archinternmed.2011.628

Finazzi, 2008, Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? No, Intern Emerg Med, 3, 197, 10.1007/s11739-008-0169-4

Barbhaiya, 2011, Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?, Curr Rheumatol Rep, 13, 59, 10.1007/s11926-010-0149-3